Literature DB >> 32339001

Outcomes and prognostic factors of tigecycline treatment for hospital-acquired pneumonia involving multidrug-resistant Acinetobacter baumannii.

Ben Liu1,2, Sha Li3, Hai-Tao Li2, Xiaokai Wang1, Hong-Yi Tan4, Shuai Liu2, Pin-Hua Pan2, Xiao-Gang Li1, Xiang-Min Li1.   

Abstract

Entities:  

Keywords:  Acinetobacter baumannii; Tigecycline; hospital-acquired pneumonia; multidrug-resistance

Year:  2020        PMID： 32339001      PMCID： PMC7218464          DOI： 10.1177/0300060520910917

Source DB:  PubMed          Journal:  J Int Med Res        ISSN： 0300-0605            Impact factor:   1.671


× No keyword cloud information.
  31 in total

1.  Clinical experience of tigecycline treatment in infections caused by extensively drug-resistant Acinetobacter spp.

Authors:  Soo-Youn Moon; Kyong Ran Peck; Hyun-Ha Chang; Shin-Woo Kim; Sang Taek Heo; Jun Seong Son; Seong Yeol Ryu; Chisook Moon; Sook-In Jung; Sang Yop Shin; Jeong-a Lee; Mi-Kyong Joung; Doo-Ryeon Chung; Cheol-In Kang; Jae-Hoon Song
Journal:  Microb Drug Resist       Date:  2012-07-09       Impact factor: 3.431

2.  Comparative in vitro activities of tigecycline and 11 other antimicrobial agents against 215 epidemiologically defined multidrug-resistant Acinetobacter baumannii isolates.

Authors:  Harald Seifert; Danuta Stefanik; Hilmar Wisplinghoff
Journal:  J Antimicrob Chemother       Date:  2006-09-14       Impact factor: 5.790

3.  Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.

Authors:  A-P Magiorakos; A Srinivasan; R B Carey; Y Carmeli; M E Falagas; C G Giske; S Harbarth; J F Hindler; G Kahlmeter; B Olsson-Liljequist; D L Paterson; L B Rice; J Stelling; M J Struelens; A Vatopoulos; J T Weber; D L Monnet
Journal:  Clin Microbiol Infect       Date:  2011-07-27       Impact factor: 8.067

4.  Assessment of coma and impaired consciousness. A practical scale.

Authors:  G Teasdale; B Jennett
Journal:  Lancet       Date:  1974-07-13       Impact factor: 79.321

5.  APACHE II: a severity of disease classification system.

Authors:  W A Knaus; E A Draper; D P Wagner; J E Zimmerman
Journal:  Crit Care Med       Date:  1985-10       Impact factor: 7.598

6.  Secular trends in Acinetobacter baumannii resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: A survey study.

Authors:  Marya D Zilberberg; Marin H Kollef; Andrew F Shorr
Journal:  J Hosp Med       Date:  2015-09-09       Impact factor: 2.960

7.  The epidemiology of sepsis in the United States from 1979 through 2000.

Authors:  Greg S Martin; David M Mannino; Stephanie Eaton; Marc Moss
Journal:  N Engl J Med       Date:  2003-04-17       Impact factor: 91.245

8.  Multidrug resistant acinetobacter.

Authors:  Vikas Manchanda; Sinha Sanchaita; Np Singh
Journal:  J Glob Infect Dis       Date:  2010-09

9.  Clinical outcomes of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii infection.

Authors:  Jung Ar Shin; Yoon Soo Chang; Hyung Jung Kim; Se Kyu Kim; Joon Chang; Chul Min Ahn; Min Kwang Byun
Journal:  Yonsei Med J       Date:  2012-09       Impact factor: 2.759

10.  Comparable Efficacy of Tigecycline versus Colistin Therapy for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Pneumonia in Critically Ill Patients.

Authors:  Won-Young Kim; Jae-Young Moon; Jin Won Huh; Sang-Ho Choi; Chae-Man Lim; Younsuck Koh; Yong Pil Chong; Sang-Bum Hong
Journal:  PLoS One       Date:  2016-03-02       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.